Heart Failure

Latest News

Focused Cardiac Ultrasonography Offers Greater Sensitivity for Identifying LV Dysfunction

Clinicians must recognize situations in which formal echocardiography should be pursued as well as the inherent limitations of focused cardiac ultrasonography.

Greater Risk for Sudden Cardiac Death in Comorbid Heart Failure and HIV

The risk of sudden cardiac death was present across all strata of left ventricular ejection fraction and was related to the use of cocaine, lower use of beta-blockers, lower CD4, and nonsuppressed viral load.

Trial Evaluating Sacubitril/Valsartan for HFpEF Misses Primary End Point

Novartis announced results from the phase 3 PARAGON-HF study evaluating the safety and efficacy of sacubitril/valsartan in HFpEF.

Efficacy of High-Dose Spironolactone for Decompensated HF Resistant to Loop Diuretics

Investigators analyzed the safety and efficacy of high-dose spironolactone to treat select patients with acute decompensated heart failure.

Higher Plasma Eicosapentaenoic Acid Linked to Lower Risk for Heart Failure

Higher plasma eicosapentaenoic acid was significantly associated with reduced risk for heart failure.

Excess Risk for Diabetes-Linked Heart Failure Significantly Greater in Women

The excess risk for heart failure associated with diabetes is significantly greater in women than men.

Empagliflozin Given Fast-Track Designation for Chronic Heart Failure

The FDA has granted Fast Track designation to empagliflozin for the reduction of the risk of cardiovascular death and hospitalization in patients with chronic heart failure.

Efficacy of Cardiac Resynchronization for Nonspecific Intraventricular Conduction Delay

Patients with nonspecific intraventricular conduction delay and QRS duration <150 ms orright bundle branch block may not benefit from cardiac resynchronization therapy with defibrillator, compared with implantable cardioverter-defibrillator therapy alone.

Intramyocardial Cell Therapy Revascor Gets Orphan Drug Designation

Revascor is a cell therapy that consists of 150 million allogeneic mesenchymal precursor cells and is delivered as a single intra-myocardial injection.

HFpEF With Severe Pulmonary Hypertension Linked to Increased Mortality

Patients with heart failure, severe pulmonary hypertension, and a preserved ejection fraction of ≥50% had a worse prognosis when compared with other patients with heart failure and severe pulmonary hypertension.